Hims & Hers CEO addresses FTC lawsuit today
Andrew Dudum, CEO of Hims & Hers, commented on the FTC lawsuit concerning the company’s GLP-1 medications and artificial intelligence applications.
Hims & Hers CEO responds to FTC lawsuit
Andrew Dudum, CEO of Hims & Hers, spoke about the recent lawsuit filed by the U.S. Federal Trade Commission (FTC) against the company. The lawsuit involves issues related to GLP-1 drugs and the use of artificial intelligence in the company’s services.
Company’s stance on the allegations
Dudum stated that the FTC misunderstands how Hims & Hers operates and emphasized that the company complies with all relevant regulations and standards. He highlighted that the GLP-1 medications offered are safe and effective, and the use of AI aims to enhance customer service.
Importance of innovation in healthcare
According to Dudum, innovations including AI integration help the company provide quality services and expand access to modern medical treatments. He believes this approach benefits consumers and supports industry development.
Next steps
Hims & Hers intends to work closely with regulators to address the concerns raised in the lawsuit. The company reaffirms its commitment to transparency and responsible business practices.
Source: CNBC Business
For the latest currency exchange rates, visit our rates page.
Source: CNBC Business
Live AEX rates